Hemato-oncology

Kite, a Gilead company, focuses on the development and delivery of paradigm-changing drugs for cancer treatment.

CAR-T (Chimeric Antigen Receptor) cells, which express a chimeric antigen receptor, represent the culmination of multiple scientific advances in the last three decades. In Belgium, these treatments are already available for the treatment of patients with specific types of lymphomas.